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Abstract: 
Objectives: To evaluate the impact of unstructured ART treatment interruption (TI) on 
arterial stiffness in adult Malawians ≥35 years on ART. 
Design: The number of TI events >30 days and >90 days during ART treatment were 
quantified in patients ≥35 years using retrospective routinely collected clinic data. TI data 
were linked to patient carotid femoral pulse wave velocity (PWV) with a threshold clinically 
relevant to CVD risk (PWV >10 m/s). 
Methods: PWV was measured in patients (on ART >18 months), during routine ART clinic 
visits in Blantyre, Malawi between November 2014 and July 2015. Multivariable logistic 
regression was used to estimate the risk of PWV>10 m/s associated with TI, controlling for 
demographic and cardio-metabolic risk factors. 
Results: In 220 patients (median age; range), 123(55.9%) had >1 TI event >30 days; 61 
(27.7%) had > 1 TI event > 90 days.  Median length of TI events was 75 days (range: 31 days 
to 8 years). Overall, 31 (14%) patients had a PWV>10 m/s. In multivariable analysis, there 
was greater than a 2-fold increased risk of PWV>10 m/s per TI event >90 days (aOR: 2.6 95% 
CI: 1.1, 6.3)(Table 1), compared to patients with no TI event.  
Conclusion: TI in ART patients ≥35 years is a common and important risk factor for arterial 
stiffness, and therefore the link between TI and CVD in this setting where traditional risks 
factors are less prevalent needs to be explored further. 
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 Introduction 
There is compelling evidence that Sub-Saharan Africa (SSA) is on the verge of a 
cardiovascular disease (CVD) epidemic, led by rising hypertension and obesity rates in urban 
populations[1-3]. In countries with a high HIV burden, this CVD epidemic will overlap with 
an HIV infected population where successful scale-up of ART has led to rising HIV prevalence 
among middle aged adults (>35 years). ART patients are potentially an important risk group 
for CVD in SSA. HIV has been associated with an approximate 50% increased risk of CVD 
compared to HIV-uninfected populations [4], which is attributable to both ART and HIV per 
se[4-6]. Key causal mechanisms underlying this increased risk relate to arterial inflammation 
and atherosclerosis in association with HIV-driven immune activation[7, 8]. Whilst on-going 
immune activation occurs in about 20% of patients with suppressed viral load [9], 
unstructured ART treatment interruption (TI) leading to systemic inflammation may cause a 
rise in cardiovascular risk biomarkers and therefore an increased risk of CVD. In randomized 
trials, structured ART treatment interruption (structured TI) was significantly associated with 
elevated levels of markers of systemic inflammation and endothelial activation [10, 11] in 
adults initiating ART in Thailand and South Africa; secondary analysis of SMART trial data 
from the US showed structured TI resulted in a 57% increase in CVD events [12].  
TI is therefore a potentially important modifiable risk factor for CVD in ART patient 
populations in SSA. However, currently there are very limited data regarding the 
relationship between TI and CVD risk in ART patients in SSA, where the prevalence of co-
factors, including background immune activation from other infectious diseases, obesity, 
diet and smoking may differ from other world regions. Carotid-femoral pulse wave velocity 
(PWV) is a non-invasive measure of arterial stiffness. In meta-analysis, PWV> 10m/s was 
associated with an approximate doubling of risk of CVD[13]. Here we examine the impact of 
TI on arterial stiffness in adults ≥35 years with HIV infection and therefore CVD risk in a 
typical urban ART Clinic in Malawi.  
 
Methods 
Adult patients receiving ART at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi 
were recruited from November 2014 to July 2015 for measurement of PWV and 
retrospective, longitudinal analysis of TI. QECH is a large teaching hospital for Malawi’s 
Southern Region. Since 2004, the QECH ART clinic has offered ART treatment according to 
Malawi Ministry of Health guidelines free-of-charge. In 2014, the clinic initiated 
approximately 1500 adults onto ART, and had 12000 adults under follow-up. Since 2008, the 
clinic has maintained an electronic medical system (EMS) into which clinicians prospectively 
enter demographic, clinical and ART patient-level data; data on patient visits before 2008 
have been retrospectively captured and validated [14].  From 2003 until 2006, eligibility 
criteria for ART initiation in adults (≥15 years) were diagnosis of a WHO stage 3 or 4 defining 
illness, or a CD4 count of <200 cells/μl, or a total lymphocyte count <1200 cells/μl with a 
clinical diagnosis of WHO stage 2 or greater. The CD4 count threshold was raised to <250 
cells/μl in 2006 and to <350 cells/μl in 2011.  HIV infection in pregnancy, regardless of CD4 
count was added as a criterion for ART initiation in 2011 (Option B+). ART visits occur 
monthly for 3 months following ART initiation and thereafter every 3 months or as clinically 
indicated. ART is dispensed at each routine clinic visit.  Inclusion criteria were: age >35 
years, enrolled in ART for >18 months, ART initiation and all follow-up at the QECH ART 
clinic, attending a routine ART appointment, not critically ill at the time of enrolment and 
not pregnant. Blood pressure, weight, height and waist circumference were measured at a 
single study visit. PWV was measured (sternal notch to femoral cuff) according to expert 
consensus guidelines on the Vicorder system [15]; PWV > 10 m/s was set as the threshold of 
clinically significant CVD risk [15]. Fasting glucose, total and HDL cholesterol and HIV viral 
load were measured.  Study visit data were linked to patient TI clinical history data from the 
EMS. Ethical approval was obtained from the University of Malawi College of Medicine 
Ethics Committee (Protocol # P.07/14/1598).  
 
Statistical Analysis 
We used logistic regression to estimate risk of PWV >10 m/s associated with TI, where risk 
was expressed as Odds Ratios (OR) with associated 95% confidence intervals (95% CIs) . TI 
events were defined a patient being at least 31 days and 91 days overdue for a scheduled 
ART visit; ART can only be obtained from these visits. Demographic and clinical factors were 
examined in univariate logistic models of PWV> 10 m/s; factors included age, sex, education 
level, years on ART, ART regimen (initial and current), body mass index, blood pressure, total 
cholesterol, high density lipoprotein (HDL) cholesterol, fasting glucose, CVD behavioural risk 
factors, year of ART initiation, current HIV viral load and TI. Factors significant at a univariate 
p-value of <0.20 were candidate factors in the multivariable model. Backwards selection of 
factors significant at p<0.05 was performed to develop a final multivariable model, with age, 
sex and years on ART included a priori. All statistical analysis was carried out in SAS Version 
9.3 (Cary, NC).  
 
Results 
We recruited 230 ART patients ≥35 years from the QECH ART clinic; median length on ART 
was 6.5 years (range: 1.8, 13.1). Three patients were not linked to ART EMS clinic data, 1 
patient declined PWV measurement, and 6 patients were missing co-factor data; our final 
analysis included 220 patients. Patient median age was 44 years (range 35 to 80), 60% were 
female and 36% had completed secondary education; 97% had been initiated on first line 
ART consisting of D4T,3TC and nevirapine (Table 1).  Patients had a low prevalence of 
reported alcohol consumption (6.4%) and cigarette smoking (1.8%). Prevalence of 
overweight or obesity was 22%.  Hypertension was prevalent in the patient cohort (28%); a 
further 29% of patients had pre-hypertensive blood pressure levels[16] (Table 1). Two 
individuals reported prior clinical CVD event (these were myocardial infarction and stroke).     
In total, 123(55.9%) patients had > 1 TI event >30 days; of these, 26.4% had a TI 
event within 12 months prior to recruitment. Sixty-one (27.7%) of patients had > 1 TI event 
>90 days (Figure 1).  The median length of individual TI events (> 30 days) was 75 days 
(range: 31 days to 8 years). Years on ART was the only factor associated with having > 1 TI 
event >30 days (Adjusted Odds Ratio [aOR]: 2.1 95% CI: 1.4, 3.1) in a multivariable analysis 
controlling for age, gender, education, marital status and year of ART initiation– data not 
shown). 
In total, 31 (14.1%) of patients had PWV>10 m/s; median PWV was 8.0 (range: 4.2, 
12.4). In multivariable analysis, we found greater than a 2-fold increased risk of PWV>10 
m/s per TI event >90 days (aOR: 2.6 95% CI: 1.1, 6.3)(Table 1).  A single TI event >30 days 
was not significantly associated with PWV >10 m/s, however >2 TI events >30 days was 
marginally associated with a 3 times the risk of PWV>10 m/s (aOR: 3.6 95% CI: 0.9, 13.8, p-
value=0.06). Older age, and hypertension were strongly associated with PWV>10 m/s (Table 
1). Detectable viral load, current ART regimen, years on Stavudine containing ART regimen, 
years on any ART regimen, total cholesterol, HDL cholesterol, blood glucose and body mass 
index were not significantly associated with PWV >10 m/s. Patients with PWV >10 m/s were 
3.5 times more likely to have experienced symptoms consistent with CVD (chest pain, 
shortness of breath, oedema, hemiplegia), though this was not statistically significance (p-
value=0.08, multivariable analysis controlling for age, gender and mean systolic blood 
pressure – data not shown).   
We re-ran our main multivariable logistic models of PWV> 10 m/s in two strata of 
time since most recent TI ‘> 36 months ago’ and ‘< 36 months ago’, using patients with no TI 
as the comparator group in both models. In the strata ‘>36 months ago’, the aOR for > 1 TI 
event > 90 days was 10.8 (95% CI; 1.7, 68.7) compared to an aOR of 2.3 (95% CI: 0.45, 10.6) 
in the strata ‘<36 months ago’. 
 
Discussion 
We report a high prevalence of TI in an adult long-term ART patient cohort  ≥35 years 
attending routine ART clinic appointments in Malawi. Similarly high levels of TI (of >30 days) 
have been observed in other African ART patient cohorts, including South Africa (41%)[17] 
and Ivory Coast (53.4%)[18].  In the context of these frequent gaps, we found a significant 
association with arterial stiffness (PWV >10 m/s) which implies a high risk of CVD.  
We found a greater than 2-fold increased risk of PWV>10 m/s per TI event >90 days, 
when controlling for other important CVD risk factors. This finding is consistent with 
evidence from intervention studies in industrialised countries demonstrating that structured 
TI is associated with higher levels of soluble markers of systemic inflammation and 
endothelial dysfunction and greater risk of CVD clinical events [10-12]. Clinical trials of 
structured TI on CVD risk report on effects only up to 36 months. We found that TI-
associated risk of arterial stiffness persisted beyond 36 months and may worsen over time.  
There were some limitations in our study. Our data derived from a small, 
observational study and may thus be subject to confounding by unmeasured factors. For 
example, inflammatory illnesses such as tuberculosis may have contributed to some TI 
events. However, the strength of the effect of TI on arterial stiffness, the fact that this effect 
had a dose-response and the biological evidence supporting this effect leads us to conclude 
that confounding of this type would have minimal impact on our findings. Although 
retrospective, TI data were collected independently in real time and thus are likely to be 
largely unbiased. We note that our study sample represents patients that survived at least 
18 months on ART, and therefore is not generalizable to patients in the period of early ART. 
However, SMART trial patients in the structure TI arm experienced a continuous rise in CVD, 
renal and hepatic disease events starting by about 6-months post-randomization[19], which 
suggests that TI-associated CVD risk begins early on.   
In conclusion, we have identified an important, prevalent and potentially modifiable 
CVD risk factor in an African ART patient population, where traditional CVD risk factors are 
considerably less prevalent than in industrialized countries. Factors associated with TI in 
African ART patient cohorts include male gender [17], lower education level [20], adverse 
drug effects[21], longer time on ART[17] and higher CD4+ T-cell count at ART initiation[17, 
20, 22]. Structural factors including travel costs, inconvenient clinic hours and discontinuous 
drug supply have also been identified as causes [18, 21, 23].  Appropriate medical, structural 
or behavioural interventions to reduce TI-associated arterial stiffness should be tested to 
avoid the potential epidemic of CVD in this growing population of middle-aged ART patients 
in SSA. 
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 N(%) N(%) N(%) OR 95% CI p-value OR 95% CI 
p-
value 
Female 133 (60) 22 (17) 111 (83)         
Male 87 (40) 11 (13) 76 (87) 0.73 0.33, 1.59 0.429 0.79 0.30, 2.11 0.643 
            
Age            
35-44 111 (50) 8 (7) 103 (93)         
45-54 68 (31) 9 (13) 59 (87) 1.96 0.72, 5.36 0.188 2.18 0.68, 6.97 0.188 
55-64 33 (15) 10 (30) 23 (70) 5.60 1.99, 15.74 0.001 2.91 0.83, 10.24 0.097 
65+ 8 (4) 6 (75) 2 (25) 38.62 6.68, 223.29 <0.001 14.07 1.94, 101.93 0.009 
            
Education level            
Non/Primary 58 (26) 9 (16) 49 (84)         
Some Secondary  83 (38) 13 (16) 70 (84) 1.01 0.40, 2.55 0.981     
Secondary or higher 79 (36) 11 (14) 68 (86) 0.88 0.34, 2.29 0.794     
            
Baseline WHO stage            
Stage 1 or 2 86 (44) 9 (10) 77 (90)         
Stage 3 or 4 110 (56) 19 (17) 91 (83) 1.79 0.76, 4.18 0.181     
            
            
Current ART regimen            
TDF/3TC/EFV (5A) 142 (62) 18 (13) 124 (87)         
AZT/3TC/NVP (2A) 59 (26) 11 (19) 48 (81) 1.58 0.69 3.58      
d4T/3TC/EFV (3A) 14 (6) 4 (29) 10 (71) 2.76 0.78 9.71      
Other (1A/4A/6A/7A) 14 (6) 4 (29) 10 (71) 2.76 0.78 9.71 0.228     
            
Years on ART1 6.7 (1.8, 13.1) 1.20 0.99, 1.39 0.066 1.18 0.94, 1.49 0.159 
            
Years on Stavudine containing 
ART regimen1 3.8 (0, 10.4) 1.02 0.87 1.20 0.771 
    
            
Undetectable viral load 198 (90) 31 (16) 167 (84)         
Detectable viral load 21 (10) 2 (10) 19 (90) 0.57 0.13, 2.56 0.461     
            
Number of unstructured ART 
treatment gaps >30 days2        
    
0 97 (44) 12 (12) 85 (88)         
1 82 (37) 8 (10) 74 (90) 0.77 0.30, 1.97 0.581 0.92 0.29, 2.95 0.887 
2 or more 41 (19) 13 (32) 28 (68) 3.29 1.35, 8.03 0.009 4.28 1.17, 15.73 0.029 
            
Number of unstructured ART 
treatment gaps >90 days2        
    
0 159 (72) 16 (10) 143 (90)         
1 51 (23) 13 (25) 38 (75) 3.06 1.35, 6.90 0.007 3.43 1.09, 10.79 0.035 
2 or more 10 (5) 4 (40) 6 (60) 5.96 1.52, 23.37 0.011 9.49 1.09, 82.90 0.042 
            
Normotensive 3 94 (43) 1 (1) 93 (99)         
Pre-hypertensive  64 (29) 8 (13) 56 (88) 13.29 1.62, 109.05 0.016 12.87 1.49, 111.24 0.020 
Hypertensive 62 (28) 24 (39) 38 (61) 58.74 7.67, 449.77 <0.001 44.30 5.13, 382.57 0.001 
            
Blood glucose <7.0 mmol/L 208 (95) 29 (14) 179 (86)         
Blood glucose >7.0 mmol/L4 12 (5) 4 (33) 8 (67) 3.09 0.87, 10.91 0.080     
            
Tot. cholesterol >5.2 mmol/L 164 (75) 20 (12) 144 (88)         
Tot. cholesterol <5.2 mmol/L 56 (25) 13 (23) 43 (77) 2.18 1.00, 4.73 0.049 2.03 0.74, 5.54 0.168 
            
HDL cholesterol > 1.03 mmol/L 136 (60) 19 (14) 117 (86)         
HDL cholesterol < 1.03 mmol/L 91 (40) 18 (20) 73 (80) 1.50 0.75, 3.08 0.248     
            
Body Mass Index            
<18.5 34 (15) 6 (18) 28 (82)         
18.5-24.99 144 (63) 23 (16) 121 (84) 0.89 0.33, 2.38 0.812     
25-29.999 38 (17) 7 (18) 31 (82) 1.06 0.31, 3.51 0.932     
>30 13 (6) 1 (8) 12 (92) 0.39 0.04, 3.58 0.404     
 
1. Median and range 
2. Parsimonious models included either ‘treatment gap >30 days’  or ‘treatment gap >90 days’. OR estimates reported here are from parsimonious 
containing ‘treatment gap >90 days’; in parsimonious model with ‘treatment gap >30 days’ change in ORs is <10%, except for total cholesterol which fell 
to 1.64 
3. Pre-hypertensive blood pressures was defined as systolic 120–139 mmHg and/or a diastolic blood pressure of 80–89 mmHg) 
4. or on blood glucose lowering medication 
 
 
